Mofezolac

Research use only, not for human use.

Mofezolac (formerly known as Disopain or N-22) is a highly selective COX-1 (cyclooxygenase-1) inhibitor with COXs selectivity index > 6000.

Mofezolac (formerly known as Disopain or N-22) is a highly selective COX-1 (cyclooxygenase-1) inhibitor with COXs selectivity index > 6000.(In Vitro):Mofezolac inhibits platelet aggregation with an IC50 of 0.45 μM in human platelet rich plasma (hPRP) assay.Mofezolac slightly increase Bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor Bortezomib.(In Vivo):Mofezolac (1-30 mg/kg; oral administration; once) treatment results in the suppression of writhing induced by the intraperitoneal injection of phenyl-p-benzoquinone in mice.

Mofezolac inhibits platelet aggregation with an IC50 of 0.45 μM in human platelet rich plasma (hPRP) assay. Mofezolac slightly increase Bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor Bortezomib.

Mofezolac (1-30 mg/kg; oral administration; once) treatment results in the suppression of writhing induced by the intraperitoneal injection of phenyl-p-benzoquinone in mice. Animal Model:Female ddY mice (4 week old, 18-27 g) injected with phenyl-p-benzoquinone (PQ) Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg Administration:Oral administration; once Result:Dose-dependently suppressed the writhing induced by PQ injection in mice.

——

Chromatin/Epigenetic

COX

COX

Inflammation/Immunology

Musculoskeletal disorders; Pain; Postoperative pain; Rheumatic disorders

78967-07-4

339.35

C19H17NO5

>98% (HPLC)

DMSO:10 mM;Water:Insoluble;Ethanol:Insoluble

COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1

2-(34-bis(4-methoxyphenyl)isoxazol-5-yl)acetic acid

(-20℃)

With Ice Pack

≥ 2 years